Targeted lung denervation modulates the mucosal epithelial transcriptome in COPD

This is the authors' abstract. We don't add key points for this paper.

Targeted lung denervation (TLD) is a novel treatment for COPD with evidence of a potential beneficial effect on exacerbation frequency [1]. It is a minimally invasive procedure involving the ablation of the airway nerve trunks of the vagus nerve that travel parallel to and outside the main bronchi, thereby reducing neuronal acetylcholine release. It has been postulated that TLD may share a similar mechanism of action with the inhaled long-acting muscarinic antagonists (LAMA) [2]. Footnotes This manuscript has recently been accepted for publication in the ERJ Open Research . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article. Conflict of interest: Dr. Bonta reports other from Nuvaira, during the conduct of the study. Conflict of interest: Dr. Deslee reports personal fees from Nuvaira, during the conduct of the study; personal fees from BTG.Pneumrx, personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from Chiesi, personal fees from AstraZeneca, outside the submitted work. Conflict of interest: Dr. Gesierich reports personal fees from PulmonX, grants from PneumrX/BTG, personal fees from Astra Zeneca, outside the submitted work. Conflict of interest: Dr. Gosens reports other from Nuvaira, during the conduct of the study; grants from Boehringer Ingelheim, grants from Novartis, grants from Aquilo, outside the submitted work; and Scientific advisor for Aquilo. Conflict of interest: Dr. Darwiche has nothing to disclose. Conflict of interest: Dr. Srikanthan has nothing to disclose. Conflict of interest: Dr. Slebos reports grants, non-financial support and other from Nuvaira, Minneapolis, MN, USA, during the conduct of the study. Conflict of interest: Dr. Kistemaker reports and LK is an employee of Aquilo BV.